Walvax BioTech (300142)

Shenzhen
67.60
+0.29(+0.43%)
  • Volume:
    36,044,465
  • Bid/Ask:
    67.59/67.60
  • Day's Range:
    66.60 - 68.79
  • Type:Equity
  • Market:China
  • ISIN:CNE100000WN2

300142 Overview

Prev. Close
67.31
Day's Range
66.6-68.79
Revenue
3.5B
Open
67.38
52 wk Range
33.59-96.73
EPS
0.6
Volume
36,044,465
Market Cap
107.56B
Dividend (Yield)
0.05
(0.10%)
Average Vol. (3m)
43,142,179
P/E Ratio
113.07
Beta
1.21
1-Year Change
59.62%
Shares Outstanding
1,591,158,474
Next Earnings Date
Mar 24, 2022
What is your sentiment on Walvax BioTech?
or
Market is currently closed. Voting is open during market hours.

Walvax BioTech Company Profile

Employees
1237
Market
China

Walvax Biotechnology Co., Ltd., a biological pharmaceutical company, researches and develops, produces, and sells bio-medicine products in China. The company offers biomedicines, such as vaccines, blood products, and others. It provides Group A, C meningococcal polysaccharide conjugate vaccine for infants below or equal to 2 years preventing diseases, such as cerebrospinal meningitis and septicemia; Group A and C meningococcal polysaccharide vaccine for in adults and children over the age of 2 years and adults to prevent disease caused by the bacterium Neisseria meningitidis group A or group C; and Group ACYW135 meningococcal polysaccharide vaccine for children above 2 years old to prevent epidemic cerebrospinal meningitis caused by Neisseria meningitidis group A, C, Y, and W135. The company also offers haemophilus influenzae type b conjugate vaccine for children from the age of 2 months to 5 years for the prevention of infectious diseases, including meningitis, pneumonia, septicemia, cellulitis, arthritis, epiglottitis, etc. In addition, it provides diphtheria, tetanus, and acellular pertussis combined vaccine for the prevention of diphtheria, tetanus, and pertussis for individuals from the age of 3 months to 6 years; and 23-valent pneumococcal polysaccharide vaccine for children above 2 years old to prevent pneumococcal disease caused by 23 serotypes. Walvax Biotechnology Co., Ltd. was founded in 2001 and is headquartered in Kunming, China.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralBuyBuyStrong BuyBuy
Technical IndicatorsStrong SellSellStrong BuyStrong BuyBuy
SummarySellNeutralStrong BuyStrong BuyBuy
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.